Recent trends in the treatment of chronic hepatitis C.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Bae, Si Hyun | - |
dc.contributor.author | Lee, Youn Jae | - |
dc.date.accessioned | 2022-07-16T16:15:52Z | - |
dc.date.available | 2022-07-16T16:15:52Z | - |
dc.date.created | 2021-05-13 | - |
dc.date.issued | 2012-03 | - |
dc.identifier.issn | 1738-222X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/166086 | - |
dc.description.abstract | Pegylated interferon and ribavirin combination therapy is accepted as the standard antiviral treatment for chronic hepatitis C regardless of HCV genotype. This combination therapy achieves higher response rates than previous therapy, but, nevertheless, a large proportion of patients suffer from treatment failure or adverse events. Recent clinical studies of viral kinetics during antiviral treatment have led to the introduction of response-guided therapy, the concept of 'customized therapy depending on viral response', which focuses on modulation of the treatment period depending on the viral response to create a sustained viral response without unnecessary medication and costs. New upcoming direct-acting antivirals (DAAs) maximize response rate, and triple therapy including DAAs along with pegylated interferon and ribavirin combination therapy could soon be the standard therapy. In this article, we reviewed the factors affecting treatment, response guided treatment, retreatment after failure of standard treatment, management of adverse events during treatment, and new treatment options. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | The Korean Association for the Study of the Liver | - |
dc.title | Recent trends in the treatment of chronic hepatitis C. | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jun, Dae Won | - |
dc.identifier.doi | 10.3350/kjhep.2012.18.1.22 | - |
dc.identifier.scopusid | 2-s2.0-84864867830 | - |
dc.identifier.bibliographicCitation | The Korean journal of hepatology, v.18, no.1, pp.22 - 28 | - |
dc.relation.isPartOf | The Korean journal of hepatology | - |
dc.citation.title | The Korean journal of hepatology | - |
dc.citation.volume | 18 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 22 | - |
dc.citation.endPage | 28 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scopus | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | erythropoietin | - |
dc.subject.keywordPlus | macrogol derivative | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | peginterferon alpha2b | - |
dc.subject.keywordPlus | proteinase inhibitor | - |
dc.subject.keywordPlus | recombinant protein | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | virus RNA | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | hemolytic anemia | - |
dc.subject.keywordPlus | hepatitis C | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | personalized medicine | - |
dc.subject.keywordPlus | review | - |
dc.subject.keywordPlus | Anemia, Hemolytic | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Erythropoietin | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Individualized Medicine | - |
dc.subject.keywordPlus | Interferon-alpha | - |
dc.subject.keywordPlus | Polyethylene Glycols | - |
dc.subject.keywordPlus | Protease Inhibitors | - |
dc.subject.keywordPlus | Recombinant Proteins | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | RNA, Viral | - |
dc.identifier.url | https://www.e-cmh.org/journal/view.php?doi=10.3350/kjhep.2012.18.1.22 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.